What is the current Price Target for the Tvardi Therapeutics stock?

The average Tvardi Therapeutics target price is $10.20. This is 844.44% higher than the current stock price. The highest price target is 1,261.11%, the lowest is 180.56%. 10 Analysts have issued a price target Tvardi Therapeutics 2027 .

How high will the Tvardi Therapeutics stock rise?

No reliable answer can be given as to how high the Tvardi Therapeutics stock will rise. The performance of stocks, including the Tvardi Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Tvardi Therapeutics stock today?

The performance of Tvardi Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Tvardi Therapeutics stock fall?

The decline in Tvardi Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Tvardi Therapeutics Forecast, price target & analysts

$1.08

5.26%

Nasdaq, Oct 06, 04:00 pm EDT.

ISIN

US1407553072

Symbol

TVRD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Analysts Charts Ownership News Strategies

Tvardi Therapeutics Target price 2026 - Analyst rating & recommendation

Tvardi Therapeutics Classifications & Recommendation

Buy

79%

Hold

14%

Sell

Tvardi Therapeutics Price Target

Target Price	$10.20
Price	$1.08
Potential	844.44% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target Tvardi Therapeutics 2027 . The average Tvardi Therapeutics target price is $10.20. This is 844.44% register free of charge higher than the current stock price. The highest price target is $14.70 1,261.11% register free of charge , the lowest is $3.03 180.56% register free of charge .
	A rating was issued by 14 analysts: 11 Analysts recommend Tvardi Therapeutics to buy, 2 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Tvardi Therapeutics stock has an average upside potential 2027 of 844.44% register free of charge . Most analysts recommend the Tvardi Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
P/E		negative

10 Analysts have issued a Tvardi Therapeutics forecast for earnings per share. The average Tvardi Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2027	$-2.19 6.01% unlock
2028	$-2.85 30.14% unlock
2029	$-1.95 31.58% unlock
2030	$-1.62 16.92% unlock
2031	$-1.77 9.26% unlock
2032	$-2.87 62.15% unlock
2033	$-0.75 73.87% unlock

Current
2026	-0.46 18.40% unlock
2027	-0.49 6.52% unlock
2028	-0.38 22.45% unlock
2029	-0.55 44.74% unlock
2030	-0.67 21.82% unlock
2031	-0.61 8.96% unlock
2032	-0.38 37.70% unlock
2033	-1.44 278.95% unlock

Tvardi Therapeutics...

Current Tvardi Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
BTIG	Locked ➜ Locked	Locked	Jul 30 2026
Raymond James	Locked ➜ Locked	Locked	Jul 08 2026
BTIG	Locked ➜ Locked	Locked	Jul 07 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 08 2026
Barclays	Locked ➜ Locked	Locked	Apr 20 2026
Barclays	Locked ➜ Locked	Locked	Apr 01 2026
Piper Sandler	Locked ➜ Locked	Locked	Apr 01 2026

Analyst Rating	Date
Locked BTIG: Locked ➜ Locked	Jul 30 2026
Locked Raymond James: Locked ➜ Locked	Jul 08 2026
Locked BTIG: Locked ➜ Locked	Jul 07 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 08 2026
Locked Barclays: Locked ➜ Locked	Apr 20 2026
Locked Barclays: Locked ➜ Locked	Apr 01 2026
Locked Piper Sandler: Locked ➜ Locked	Apr 01 2026

Discover more stocks with a high price target

NIO ADR 80.99%

Alibaba Group Holding Ltd 80.17%

Rheinmetall 71.25%

Tencent Holdings Ltd. 61.51%

Adyen 55.29%

Uber Technologies 49.13%

BYD 48.99%

TUI 42.81%

Infineon 42.72%

Siemens Energy 41.82%

Adidas 40.54%

Netflix 40.33%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now